Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD117-targeted CAR-T cells (Zhujiang Hospital)
- Development stage
- Unknown
- Lead developer
- Southern Medical University Zhujiang Hospital
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
CD117-targeted CAR-T cells (Zhujiang Hospital) is an experimental chimeric antigen receptor (CAR) T-cell therapy being developed for the treatment of relapsed or refractory acute myeloid leukemia (AML). The therapy involves genetically engineering a patient's T cells to express a CAR that specifically targets CD117 (also known as c-Kit or Mast/stem cell growth factor receptor Kit). CD117 is a type III receptor tyrosine kinase that is essential for the survival and proliferation of hematopoietic stem cells and is frequently overexpressed on the surface of AML blasts. By directing T cells to recognize CD117, the therapy aims to selectively eliminate leukemic cells. This program is part of a broader clinical research initiative at Zhujiang Hospital evaluating multiple CAR-T targets, including CD33, CD38, and CD123, to address the high heterogeneity of AML.
- Other names
- anti-CD117 CAR-Tanti-CD-117 CAR-Tanti-CD 117 CAR-TCD117 CAR-TCD-117 CAR-TCD 117 CAR-T
02
Targets
KIT (c-KIT proto-oncogene receptor tyrosine kinase)
Beyond the preview
Go deeper on CD117-targeted CAR-T cells (Zhujiang Hospital).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD117-targeted CAR-T cells (Zhujiang Hospital).